Inogen (INGN) Hits New 1-Year High at $130.52

Inogen Inc (NASDAQ:INGN) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $130.52 and last traded at $126.84, with a volume of 129100 shares trading hands. The stock had previously closed at $126.84.

A number of research analysts have recently issued reports on the company. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 14th. Piper Jaffray Companies raised Inogen from a “neutral” rating to an “overweight” rating in a report on Tuesday. BidaskClub raised Inogen from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. Finally, Needham & Company LLC upped their price objective on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $103.71.

The firm has a market capitalization of $2,699.79, a price-to-earnings ratio of 105.28, a price-to-earnings-growth ratio of 4.21 and a beta of 1.02.

In other Inogen news, CFO Alison Bauerlein sold 11,718 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $115.87, for a total transaction of $1,357,764.66. Following the sale, the chief financial officer now directly owns 11,718 shares in the company, valued at $1,357,764.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Scott Wilkinson sold 30,651 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $115.75, for a total value of $3,547,853.25. Following the sale, the insider now owns 38,107 shares in the company, valued at $4,410,885.25. The disclosure for this sale can be found here. Insiders have sold 157,236 shares of company stock worth $18,565,043 in the last ninety days. 5.31% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of INGN. UBS Asset Management Americas Inc. boosted its position in Inogen by 148.1% during the second quarter. UBS Asset Management Americas Inc. now owns 7,939 shares of the medical technology company’s stock worth $758,000 after purchasing an additional 4,739 shares in the last quarter. California Public Employees Retirement System boosted its position in Inogen by 8.6% during the second quarter. California Public Employees Retirement System now owns 20,200 shares of the medical technology company’s stock worth $1,927,000 after purchasing an additional 1,600 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Inogen by 63.6% during the second quarter. Parametric Portfolio Associates LLC now owns 45,969 shares of the medical technology company’s stock worth $4,386,000 after purchasing an additional 17,867 shares in the last quarter. Voya Investment Management LLC boosted its position in Inogen by 13.7% during the second quarter. Voya Investment Management LLC now owns 7,610 shares of the medical technology company’s stock worth $726,000 after purchasing an additional 917 shares in the last quarter. Finally, Stifel Financial Corp purchased a new stake in Inogen during the second quarter worth $238,000.

TRADEMARK VIOLATION WARNING: “Inogen (INGN) Hits New 1-Year High at $130.52” was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://weekherald.com/2018/02/23/inogen-ingn-hits-new-1-year-high-at-130-52.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply